Indaptus Therapeutics, INC Schedule 13D activist filings

Sino Lion Ventures Limited and Chenhao Xu filed an amendment to their Schedule 13D regarding their 29.19% stake in Indaptus Therapeutics, Inc.

Junyi Dai reports a change in his beneficial ownership percentage of Indaptus Therapeutics due to an increase in the company's total outstanding shares.

Ting Yang filed an amendment to his Schedule 13D disclosing an 8.44% beneficial ownership stake in Indaptus Therapeutics, Inc. following a dilution event.

Yun Yao discloses a 31.51% beneficial ownership stake in Indaptus Therapeutics, Inc. following a dilution event.

Several significant shareholders in Indaptus Therapeutics have formally disbanded their reporting group, with one shareholder falling below the 5% ownership threshold.

A group of investors led by Yun Yao acquired a controlling stake in Indaptus Therapeutics, leading to a significant change in beneficial ownership and the appointment of a new CEO.

David E. Lazar, co-Chief Executive Officer of Indaptus Therapeutics, Inc., sold a significant portion of his preferred stock holdings for $11.2 million and resigned from his co-CEO role, while remaining on the Board of Directors.

David E. Lazar has acquired a 98% beneficial ownership stake in Indaptus Therapeutics Inc. and has been appointed Co-Chief Executive Officer and a Board member.

Michael J. Newman, a key insider at Indaptus Therapeutics, Inc., increased his beneficial ownership to 5.4% and entered into a voting agreement supporting board proposals.

Jeffery A. Meckler increased his beneficial ownership in Indaptus Therapeutics to 12.7% and entered into a voting agreement supporting board proposals following a $6.0 million preferred stock sale.